ReviewAAPS PharmSciTech2011
Pectin matrix as oral drug delivery vehicle for colon cancer treatment.
Review in AAPS PharmSciTech, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 202 citations in OpenAlex.
- Synthesis, Characterization,Current drug delivery · 2026Article
- Natural Polymers Based Biocompatible Nanomedicines for Targeting Colon Cancer: Prospects and Challenges.International journal of nanomedicine · 2026Review
- Antimicrobial therapeutic protein extraction from fruit waste and recent trends in their utilization against infections.Bioprocess and biosystems engineering · 2024Review
- Anti-oxidant and anti-inflammatory potential of different polymer-based mesalamine delayed-release granules in TNBS-induced ulcerative colitis in wistar rats.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- Characteristics of Interpolyelectrolyte Complexes Based on Different Types of Pectin with EudragitInternational journal of molecular sciences · 2023Article
- Preparation andInternational journal of pharmaceutics: X · 2023Article
- Aerogels as Carriers for Oral Administration of Drugs: An Approach towards Colonic Delivery.Pharmaceutics · 2023Review
- Review
- Soluble Dietary Fibers as Antihyperlipidemic Agents: A Comprehensive Review to Maximize Their Health Benefits.ACS omega · 2023Review
- How to Develop Drug Delivery System Based on Carbohydrate Nanoparticles Targeted to Brain Tumors.Polymers · 2023Review
- Advances in Polysaccharide-Based Oral Colon-Targeted Delivery Systems: The Journey So Far and the Road Ahead.Cureus · 2023Review
- Article
- Review
- Targeted Delivery Methods for Anticancer Drugs.Cancers · 2022Review
- Prospects of Curcumin Nanoformulations in Cancer Management.Molecules (Basel, Switzerland) · 2022Review
- Anti-Cancer Pectins and Their Role in Colorectal Cancer Treatment.Onco therapeutics · 2022Article
- Review
- Newly Obtained Apple Pectin as an Adjunct to Irinotecan Therapy of Colorectal Cancer ReducingCancers · 2021Article
- Performant Composite Materials Based on Oxide Semiconductors and Metallic Nanoparticles Generated from Cloves and Mandarin Peel Extracts.Nanomaterials (Basel, Switzerland) · 2020Article
- Pectin-Tannic Acid Nano-Complexes Promote the Delivery and Bioactivity of Drugs in Pancreatic Cancer Cells.Pharmaceutics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colon cancer is the fourth most common cancer globally with 639,000 deaths reported annually. Typical chemotherapy is provided by injection route to reduce tumor growth and metastasis. Recent research investigates the oral delivery profiles of chemotherapeutic agents. In comparison to injection, oral administration of drugs in the form of a colon-specific delivery system is expected to increase drug bioavailability at target site, reduce drug dose and systemic adverse effects. Pectin is suitable for use as colon-specific drug delivery vehicle as it is selectively digested by colonic microflora to release drug with minimal degradation in upper gastrointestinal tract. The present review examines the physicochemical attributes of formulation needed to retard drug release of pectin matrix prior to its arrival at colon, and evaluate the therapeutic value of pectin matrix in association with colon cancer. The review suggests that multi-particulate calcium pectinate matrix is an ideal carrier to orally deliver drugs for site-specific treatment of colon cancer as (1) crosslinking of pectin by calcium ions in a matrix negates drug release in upper gastrointestinal tract, (2) multi-particulate carrier has a slower transit and a higher contact time for drug action in colon than single-unit dosage form, and (3) both pectin and calcium have an indication to reduce the severity of colon cancer from the implication of diet and molecular biology studies. Pectin matrix demonstrates dual advantages as drug carrier and therapeutic for use in treatment of colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.